Appendix A

Claim Amendments

Claim 1. (Currently amended) A method of treating disturbances or illnesses of an inner ear, comprising administering at least one vasopressin receptor antagonist or mixtures of such antagonists to a patient in need thereof~~.~~, wherein said receptor antagonist is a vasopressin-V_2-receptor antagonist and said disturbance or illness of the inner ear is associated with at least one of the symptoms of vertigo, impairment of hearing or tinnitus and is linked with endolymphatic hydrops.

Claim 2. (Cancelled)

Claim 3. (Cancelled)

Claim 4. (Currently amended) The method of claim ~~3~~1, characterized in that the impairment of hearing is a deep sound hearing impairment.

Claim 5. (Cancelled)

Claim 6. (Previously presented) The method of claim 1, characterized in that the disturbance or illness of the inner ear is Menière's disease.

Claim 7. (Previously presented) The method of claim 1, characterized in that the receptor antagonist is a peptide compound.

Claim 8. (Currently amended) The method of claim 7, characterized in that the peptide compound is a linear peptide, ~~particularly~~ namely propionyl-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH_2.

Claim 9. (Currently amended) The method of claim 1, characterized in that the receptor antagonist is a non-peptidic, organic substance.

Claim 10. (Previously presented) The method of claim 9, characterized in that that organic substance is a benzazepin derivative.

Claim 11. (Previously presented) The method of claim 10, characterized in that the benzazapin derivative is 5-

dimethylamino-1-{4-(2-methyl-benzoylamino)-benzoyl}-2,3,4,5-tetrahydro-1H-benzazepin.

Claim 12. (Previously presented) The method of claim 9, characterized in that the organic substance is an indole derivative.

Claim 13. (Currently amended) The method of claim 12, characterized in that the indole derivative is 1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzene~~1-[4-(N-tert.-butylcarbamoyl)-2-methodxybenzene~~ sulphonyl}-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)-cyclohexane}-indol-2-one fumarate.

Claim 14. (Currently amended) The method of claim 1, characterized in that the receptor antagonist ~~can be~~is administered orally ~~and~~ or intravenously.

Claim 15. (Currently amended) The method of claim 1, characterized in that the receptor antagonist is ~~used~~ administered in a quantity of 0.1 to 50 mg/kg of body weight and per day.

Claim 16 (Currently amended) The method according to claim 1, characterized in that the receptor antagonist is contained in a

formulation or medicament intended for administration in a quantity of 1 to 75 wt.% of the composition.

Claim 17. (Cancelled)

Claim 18. (Cancelled)

Claim 19. (Cancelled)

Claim 20. (Cancelled)

Claim 21. (Currently amended) The method according to claim 16, characterized in that the receptor antagonist is contained in a formulation or medicament intended for administration in a quantity of 5 to 50 wt.% of the composition.

Claim 22. (Currently amended) The method according to claim 16, characterized in that the receptor antagonist is contained in a formulation or medicament intended for administration in a quantity of 5 to 25 wt.% of the composition.